Angiodynamics Stock Performance
| ANGO Stock | USD 9.87 0.47 5.00% |
On a scale of 0 to 100, AngioDynamics holds a performance score of 3. The firm shows a Beta (market volatility) of 0.75, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, AngioDynamics' returns are expected to increase less than the market. However, during the bear market, the loss of holding AngioDynamics is expected to be smaller as well. Please check AngioDynamics' jensen alpha, skewness, relative strength index, as well as the relationship between the value at risk and day median price , to make a quick decision on whether AngioDynamics' price patterns will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in AngioDynamics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very fragile technical and fundamental indicators, AngioDynamics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 5 | Five Day Return 7.28 | Year To Date Return 9.91 | Ten Year Return (47.08) | All Time Return (21.04) |
1 | Acquisition by Laura Piccinini of 21971 shares of AngioDynamics subject to Rule 16b-3 | 12/20/2024 |
2 | Cardiovascular Devices Market to Hit US110. Billion by 2029 with 7.3 percent CAGR MarketsandMarkets. | 01/29/2025 |
3 | AngioDynamics, Inc.s Share Price Boosted 38 percent But Its Business Prospects Need A Lift Too | 01/30/2025 |
4 | AngioDynamics Down 14.2 percent Since Last Earnings Report Can It Rebound | 02/07/2025 |
5 | Should You Add Penumbra Stock to Your Portfolio Right Now | 02/12/2025 |
6 | Several Insiders Invested In AngioDynamics Flagging Positive News | 02/24/2025 |
7 | The Cooper Companies Matches Q1 Earnings Estimates | 03/06/2025 |
8 | Acquisition by James Clemmer of 207693 shares of AngioDynamics at 7.4 subject to Rule 16b-3 | 03/07/2025 |
9 | UiPath Posts Weak Revenue, Joins SentinelOne, American Eagle And Other Big Stocks Moving Lower In Thursdays Pre-Market Session | 03/13/2025 |
10 | Acquisition by Warren Nighan of 5677 shares of AngioDynamics subject to Rule 16b-3 | 03/14/2025 |
11 | AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event | 03/19/2025 |
| Begin Period Cash Flow | 44.6 M |
AngioDynamics |
AngioDynamics Relative Risk vs. Return Landscape
If you would invest 889.00 in AngioDynamics on December 20, 2024 and sell it today you would earn a total of 51.00 from holding AngioDynamics or generate 5.74% return on investment over 90 days. AngioDynamics is currently generating 0.2337% in daily expected returns and assumes 5.7639% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than AngioDynamics, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AngioDynamics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AngioDynamics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AngioDynamics, and traders can use it to determine the average amount a AngioDynamics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0405
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ANGO | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.76 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.23 actual daily | 4 96% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average AngioDynamics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AngioDynamics by adding it to a well-diversified portfolio.
AngioDynamics Fundamentals Growth
AngioDynamics Stock prices reflect investors' perceptions of the future prospects and financial health of AngioDynamics, and AngioDynamics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AngioDynamics Stock performance.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.0584 | ||||
| Profit Margin | (0.78) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 332.87 M | ||||
| Shares Outstanding | 40.47 M | ||||
| Price To Earning | 7.90 X | ||||
| Price To Book | 2.05 X | ||||
| Price To Sales | 1.33 X | ||||
| Revenue | 303.91 M | ||||
| Gross Profit | 151.01 M | ||||
| EBITDA | (14.29 M) | ||||
| Net Income | (184.35 M) | ||||
| Cash And Equivalents | 24.56 M | ||||
| Cash Per Share | 0.31 X | ||||
| Total Debt | 5.91 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 2.28 X | ||||
| Book Value Per Share | 4.57 X | ||||
| Cash Flow From Operations | (28.16 M) | ||||
| Earnings Per Share | (5.57) X | ||||
| Market Capitalization | 382 M | ||||
| Total Asset | 317.67 M | ||||
| Retained Earnings | (395.2 M) | ||||
| Working Capital | 102.1 M | ||||
| Current Asset | 146.25 M | ||||
| Current Liabilities | 66.73 M | ||||
About AngioDynamics Performance
By examining AngioDynamics' fundamental ratios, stakeholders can obtain critical insights into AngioDynamics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that AngioDynamics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 170.51 | 158.42 | |
| Return On Tangible Assets | (0.88) | (0.84) | |
| Return On Capital Employed | (0.98) | (0.93) | |
| Return On Assets | (0.67) | (0.63) | |
| Return On Equity | (0.81) | (0.77) |
Things to note about AngioDynamics performance evaluation
Checking the ongoing alerts about AngioDynamics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AngioDynamics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AngioDynamics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 303.91 M. Net Loss for the year was (184.35 M) with profit before overhead, payroll, taxes, and interest of 151.01 M. | |
| AngioDynamics currently holds about 24.56 M in cash with (28.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.31. | |
| Over 85.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from businesswire.com: AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event |
- Analyzing AngioDynamics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AngioDynamics' stock is overvalued or undervalued compared to its peers.
- Examining AngioDynamics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AngioDynamics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of AngioDynamics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AngioDynamics' stock. These opinions can provide insight into AngioDynamics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.57) | Revenue Per Share | Quarterly Revenue Growth (0.08) | Return On Assets | Return On Equity |
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.